Zoledronic Acid: Clinical Uses, Therapeutic Effects and Pharmacokinetics


Ronald Carman (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Zoledronic acid is a third generation bisphosphonate which is administered intravenously once yearly at a dose of 5mg for multiple reasons including the treatment of post-menopausal women with osteoporosis to reduce the incidence of vertebral, hip and non-vertebral fractures and to increase bone mineral density (BMD), the prevention of clinical fractures after hip fracture in women and men, treatment of osteoporosis in men, prevention and treatment of glucocorticoid-induced osteoporosis (GIO), the prevention of post-menopausal osteoporosis (in the US) and the treatment of Paget’s disease of the bone. This book discusses the clinical uses, therapeutic effects and pharmacokinetics of zoledronic acid. (Imprint: Nova)

Table of Contents

Table of Contents


Chapter 1 – Use of Zoledronic Acid in Men and Women with Low Bone Mass (pp. 1-26)
Robin K. Dore (Clinical Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA)

Chapter 2 – Clinical and Experimental Evidences of Anti-Myeloma Activities of Zoledronic Acid (pp. 27-52)
R. Ria, A. Reale, A. Melaccio and A. Vacca (Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy)

Chapter 3 – The Use of Zoledronic Acid in Osteoarthritis: From Animal Models to Clinical Studies (pp. 53-70)
Nidhi Sofat, Anasuya Kuttapitiya and Toby Smith (Institute of Infection and Immunity, St. George’s University of London, Cranmer Terrace, London, UK, and others)

Chapter 4 – Treatment with Zoledronic Acid in Paget´s Disease of Bone (pp. 71-82)
Javier Bachiller-Corral and Walter Alberto Sifuentes-Giraldo (Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain)

Chapter 5 – Bisphosphonates: Pharmacokinetics, Clinical Uses and Safety (pp. 83-96)
Raquel Cobos and Gorka Orive (Health Research Unit of Alava, Basque Health Service, Vitoria-Gasteiz, Álava, Spain, and others)

Chapter 6 – Clinical Role of Zoledronic Acid in Adjuvant and Metastatic Breast Cancer (pp. 97-106)
Banys Malgorzata, Natalia Krawczyk and Tanja Fehm (Department of Obstetrics and Gynecology, University of Duesseldorf, Duesseldorf, Germany, and others)

Chapter 7 – Zoledronic Acid in Chronic Inflammatory Rheumatic Diseases: A Critical Evidence of its Antiresorptive and Immunomodulating Effects (pp. 107-148)
Laura Gonzalez-Lopez, Eva M. Olivas-Flores, David Bonilla-Lara, Edsaul E. Perez-Guerrero, Jessica D. Murillo-Vazquez, Tania M. Rodriguez Hernandez and Jorge I. Gamez-Nava (Department of Internal Medicine-Rheumatology, Hospital General Regional 110, IMSS and Public Health Sciences Department, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, Guadalajara Jal. México, and others)

Chapter 8 – Zoledronic Acid and Benign Bone Disease: Clinical Uses, Therapeutic Effects and Pharmacokinetics (pp. 149-172)
P. K. Wong and J. D. Wark (Mid-North Coast Arthritis Clinic, Coffs Harbour, and Rural Clinical School, Faculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia, and others)

Chapter 9 – Zoledronic Acid and Bisphosphonate Related Osteonecrosis of the Jaw (pp. 173-192)
Dileep Sharma, Stephen Hamlet, Eugen Bogdan Petcu and Saso Ivanovski (Griffith Health Institute, MBOD group, School of Dentistry and Oral Health, Griffith University Gold Coast campus QLD, and others)

Chapter 10 – Clinical Uses of Zoledronic Acid (pp. 193-218)
Colin Phipps, Ooi Wei Seong, Vin Cci Ng and Daryl Tan (Department of Haematology, Singapore General Hospital, Singapore, and others)


Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!